NOO 9 7 2006

Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/748831-Conf. #2793

		Application Number	10/748831-Conf. #2793
TRANSMITTAL		Filing Date	December 30, 2003
FORM		First Named Inventor	Richard L. BOYD
(to be used for all correspondence after initial t	filing)	Art Unit	1645
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	3	Attorney Docket Number	0286336.00155US1/NOR-012CP2

ENCLOSURES (Check all that apply)					
Fee Trans	mittal Form	Drawing(s)		After Allowance Communication to TC	
Fee	Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendme	nt/Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After	r Final	Petition to Convert to a Provisional Application		Proprietary Information	
Affid	avits/declaration(s)	Power of Attorney, Revocati Change of Correspondence		Status Letter	
Extension	of Time Request	Terminal Disclaimer		X Other Enclosure(s) (please Identify below):	
Express Abandonment Request		Request for Refund		Return Receipt Postcard	
X Supplemental Information Disclosure Statement		CD, Number of CD(s)			
Certified C Document	opy of Priority (s)	Landscape Table on	CD		
	lissing Parts/ Application	Remarks			
	y to Missing Parts under FR 1.52 or 1.53				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP				
Signature	gnature OM-Course Kolse				
Printed name	Ann-Louise Kerner, Ph.D.				
Date	April 24, 2006		Reg. No.	33,523	

	ong with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on ent postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450,
Dated: April 24, 2006	Signature: (Sarah L. Farris)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 24, 2006

Signature: (Sarah Faris)

Docket No.: 0286336.00155US1/NOR-012CP2

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Richard L. BOYD

Confirmation No.:

2793

Application No.:

10/748831

Art Unit:

1645

Filed:

December 30, 2003

Examiner:

Not Yet Assigned

Title:

HEMATOPOIETIC STEM CELL GENE THERAPY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:

This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits. No fee is required.

Applicant requests that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: April 24, 2006

Ann-Louise Kerner, Ph.D. Registration No.: 33,523 Attorney for Applicant

Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 (617) 526-6000 (telephone) (617) 526-5000 (facsimile)



PTO/SB/08a/b (07-05) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/B/PTO Application Number 10/749118-Conf. #3277 INFORMATION DISCLOSURE Filing Date December 30, 2003 STATEMENT BY APPLICANT First Named Inventor Richard L. BOYD Art Unit 1645 (Use as many sheets as necessary) Examiner Name Not Yet Assigned Sheet 1 1 Attorney Docket Number 286336.151 US1/NOR-012CP2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-6,248,329	06-19-2001	Chandrashekar et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ' Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Ellis, "New Technologies for Making Vaccines," Chapter 29 of "Vaccines", Plotkin et al., 1998, pp. 568-574.	
	СВ	Ezzell NIH Research, "Cancer 'Vaccines': An Idea Whose Time Has Come?" 1995, Vol. 7, pp. 46-49.	
	СС	Feldman et al., "Anti-TNF∞ Therapy is Useful in Rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases," Transplantation Proceeding, 1998, Vol. 30, pp. 4126-4127.	
	CD	Spitler, "Cancer Vaccines: The Interferon Analogy," Cancer Biotherapy, 1995, Vol. 10, pp. 1-3.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	
·		

¹Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.